The randomized FOURLIGHT-1 trial enrolled 264 HR-positive, HER2- metastatic breast cancer patients who progressed after prior CDK4/6 inhibitor therapy. Atirmociclib combined with fulvestrant demonstrated a 40% reduction in progression risk (HR 0.60; 95% CI 0.44–0.83; p=0.0007) compared to fulvestrant or everolimus plus exemestane, with consistent benefits across all prespecified subgroups.

Atirmociclib exhibited a manageable safety profile, with no new signals identified and only 6.4% of patients discontinuing treatment due to adverse events. These tolerability results align with prior studies and support further development of this next-generation CDK4 inhibitor.

Pfizer is advancing atirmociclib into a Phase 3 registrational trial in the first-line metastatic setting and will present detailed data from a Phase 2 neoadjuvant study in early breast cancer at an upcoming medical meeting. These efforts aim to explore earlier lines of therapy where durable endocrine-based control may provide greater patient benefit.

Positive Phase 2 data bolster Pfizer’s oncology pipeline by potentially differentiating atirmociclib within the competitive CDK inhibitor class. Successful late-stage trials could enhance Pfizer’s market position in hormone receptor-positive breast cancer and drive long-term revenue growth.